INOVIO PHARMACEUTICALS, INC.: ADAR1 Capital Management, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ADAR1 Capital Management disclosed a stake exceeding 5% in Inovio Pharmaceuticals via a Schedule 13G filing with the SEC (accession 0001104659-26-128721). The exact share count and percentage were not specified in the headline disclosure. The move signals new institutional interest in the clinical-stage DNA medicines developer. Investors will watch for further detail on the position's size and any activist intent in subsequent filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
INOVIO PHARMACEUTICALS, INC., ADAR1 Capital Management, LLC